{
    "clinical_study": {
        "@rank": "147984", 
        "acronym": "EnligHTN IV", 
        "arm_group": [
            {
                "arm_group_label": "Renal Denervation", 
                "arm_group_type": "Experimental", 
                "description": "Renal artery ablation with the EnligHTN\u2122 Renal Denervation System."
            }, 
            {
                "arm_group_label": "Sham procedure", 
                "arm_group_type": "Active Comparator", 
                "description": "Sham procedure"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and\n      effectiveness of the EnligHTN\u2122 Renal Denervation System in the treatment of subjects with\n      drug-resistant uncontrolled hypertension."
        }, 
        "brief_title": "Multi-center, Randomized, Single-blind, Sham Controlled Clinical Investigation of Renal Denervation for Uncontrolled Hypertension", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Drug-resistant Uncontrolled Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is \u226518 years of age and \u2264 80 years of age at time of informed consent for\n             participation in the clinical investigation\n\n          -  Subject must be able and willing to provide written informed consent\n\n          -  Subject must be able and willing to comply with the required follow-up schedule\n\n          -  Subject has an office Systolic Blood Pressure \u2265 160 mmHg based on an average of 3\n             Blood Pressure readings at the confirmatory visit (except for subjects with Diabetes\n             Mellitus Type II who must demonstrate an office Systolic Blood Pressure of \u2265 150\n             mmHg)\n\n          -  Subject has a daytime mean Systolic 24-hour Ambulatory Blood Pressure value of \u2265 140\n             mmHg as measured during the two week screening period and confirmed at the\n             confirmatory visit\n\n          -  Subject is taking \u2265 3 antihypertensive medications concurrently at full tolerated\n             doses (this must include one diuretic) or subject is taking a diuretic and has a\n             documented intolerance to at least two (2) out of the three (3) remaining major\n             classes of anti-hypertensives (ACE / ARB, Calcium Channel Blockers, Beta blockers and\n             is unable to take 3 anti-hypertensive drugs)\n\n             o Intolerance is defined as an absolute contraindication to an anti-hypertensive\n             medication according to the approved labeling or an inability to take an\n             anti-hypertensive medication as prescribed due to an adverse drug effect including an\n             immune mediated response or interaction with other medications.\n\n          -  Subjects must be on a stable antihypertensive medication regimen for a minimum of 2\n             weeks prior to completing the initial screening visit and the medication regimen must\n             remain unchanged during the 2 week screening period following signing consent.\n             Subject must be assessed at the confirmatory visit with no expected changes for at\n             least six (6) months\n\n        Exclusion Criteria:\n\n          -  Subject has had a previous renal denervation attempt\n\n          -  Subject has known cause of secondary hypertension other than sleep apnea\n\n          -  Subjects with significant renovascular abnormalities such as renal artery stenosis\n             >30%, previous renal stenting or angioplasty, renal artery occlusion, renal vein\n             thrombosis, renal aneurysm or renal atheroembolism\n\n          -  Subject has had a myocardial infarction, unstable angina pectoris, or cerebrovascular\n             accident < 180 days prior to enrollment\n\n          -  Subject has hemodynamically significant valvular heart disease as determined by a\n             Study Investigator\n\n          -  Subject is expected to have any cardiovascular intervention within 180 days of\n             enrollment\n\n          -  Subject has blood clotting abnormalities such as thrombocytopenia, hemophilia, or\n             significant anemia\n\n          -  Subject life expectancy is < 12 months, as determined by a Study Investigator\n\n          -  Subject is participating in another Clinical Investigation (IND or IDE)\n\n          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate\n             contraceptive methods\n\n          -  Subject has active systemic infection as determined by a Study Investigator\n\n          -  Subject has main renal arteries with diameter(s) < 4 mm in diameter or < 20 mm in\n             length or multiple renal arteries where the main renal arteries supply <75% of the\n             kidney\n\n          -  Subject has eGFR < 45 mL/min per 1.73 m2 using the Modified of Diet in Renal Disease\n             (MDRD) formula\n\n          -  Subject has evidence of significant abdominal aortic aneurysm (AAA) defined as an\n             aneurysm size of \u22655.0 cm in width and/or involving the renal arteries, and/or\n             requiring surgical or percutaneous intervention within 6 months of enrollment.\n\n          -  Subject has had >1 in-patient hospitalization for a hypertensive crisis within 12\n             months prior to enrollment\n\n          -  Subject has a condition which would interfere with the accurate interpretation of the\n             study endpoints including but not limited to orthostatic hypotension, chronic oxygen\n             support other than for sleep apnea, primary pulmonary hypertension, Type I Diabetes\n             Mellitus, pheochromocytoma, Cushing's disease, coarctation of the aorta,\n             hyperthyroidism, or hyperparathyroidism, large arm diameter that is unable to\n             accommodate the blood pressure cuff, arrhythmia that interferes with automatic pulse\n             sensing.\n\n          -  Any condition that would prohibit or interfere with the ability to obtain accurate\n             Blood Pressure measurements using the CIP specific automatic Blood Pressure monitor\n\n          -  Subject has Systolic Blood Pressure values which are greater than 20mmHg apart after\n             six (6) measurements as assessed at the confirmatory visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "590", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903187", 
            "org_study_id": "1204"
        }, 
        "intervention": [
            {
                "arm_group_label": "Renal Denervation", 
                "intervention_name": "EnligHTN Renal Denervation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Sham procedure", 
                "intervention_name": "Sham", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35801"
                    }, 
                    "name": "Heart Center Research, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72211"
                    }, 
                    "name": "Arkansas Heart Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39216"
                    }, 
                    "name": "Jackson Heart Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The primary safety endpoint will be the proportion of subjects who experience any Major Adverse Event (MAE) as adjudicated by the Clinical Event Committee (CEC).", 
                "safety_issue": "Yes", 
                "time_frame": "6 months post randomization"
            }, 
            {
                "measure": "The primary effectiveness endpoint is the reduction of Office Systolic Blood Pressure (OSBP) at six (6) months post randomization compared to baseline between groups", 
                "safety_issue": "No", 
                "time_frame": "6 months post randomization"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Device or Procedure related adverse events by severity post randomization through six (6) months", 
                "safety_issue": "Yes", 
                "time_frame": "6 months post randomization"
            }, 
            {
                "measure": "The number of subjects that experience each type of MAE", 
                "safety_issue": "Yes", 
                "time_frame": "6 months post randomization"
            }, 
            {
                "measure": "Incidence of achieving \u2265 10 mmHg, \u2265 15 mmHg, and  \u226520 mmHg reductions in OSBP", 
                "safety_issue": "No", 
                "time_frame": "6 months post randomization, and all follow-up timepoints"
            }, 
            {
                "measure": "Reduction in Ambulatory Blood Pressure (ABP) parameters", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 months post randomization, and all follow-up timepoints"
            }
        ], 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}